MSI Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

MSI Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$51K	Hold	1,318	–	–	﹤0.01%	1858
2016 Q3	$67K	Hold	1,318	–	–	﹤0.01%	1652
2016 Q2	$60K	Hold	1,318	–	–	﹤0.01%	1720
2016 Q1	$52K	Sell	1,318 -100	-7%	-$3.97K	﹤0.01%	1710
2015 Q4	$80K	Buy	1,418 +100	+8%	+$5.08K	﹤0.01%	1421
2015 Q3	$52K	Sell	1,318 -100	-7%	-$4.83K	﹤0.01%	1202
2015 Q2	$68K	Buy	1,418 +218	+18%	+$9.24K	﹤0.01%	1146
2015 Q1	$48K	Buy	+1,200	New	+$42.9K	﹤0.01%	1330

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MSI Financial Services's NBIX Position: Q4 2016 in Review

MSI Financial Services held its Neurocrine Biosciences (NBIX) position steady in Q4 2016 at 1,318 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

MSI Financial Services first reported a position in NBIX in Q1 2015 and has held it in 8 quarters since. The position peaked at $80K in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

MSI Financial Services held 1,318 shares of Neurocrine Biosciences worth $51K as of Q4 2016.
MSI Financial Services left its Neurocrine Biosciences share count unchanged in Q4 2016.
Neurocrine Biosciences made up ﹤0.01% of MSI Financial Services's portfolio in Q4 2016, its #1858 holding.
MSI Financial Services first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 8 quarters since.
MSI Financial Services's Neurocrine Biosciences position peaked at $80K in Q4 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.